EVIIVE AG Alternatives & Competitors
12 companies similar to EVIIVE AG — Unleash the full potential of liquid biopsies for the earliest disease preventio...
Companies similar to EVIIVE AG
ImmunoGenesis, Inc.
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...
Houston, United States
PIN Pharma
A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory th...
Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack...
San Diego, United States
Quentis Therapeutics
Developing innovative immuno-therapeutics to combat ER stress and empower the immune syste...
Rival Readout
Competing with EVIIVE AG? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Coley Pharmaceutical Group
Empowering the immune system to conquer illnesses and boost vaccine efficacy.
Elicio Therapeutics
Lymph-Node Targeted Immunotherapies
Boston, United States
INmune Bio Inc.
INmune Bio is focused on modulating components of the innate immune system to activate an...
Boca Raton, United States
Novelogics Biotechnology Inc.
Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer us...
Canada
Umoja Biopharma
Pioneering advanced immunotherapies to empower the body's innate ability to fight cancer b...
Red Arrow Therapeutics
Transforming powerful biology into safe therapies through pH-responsive nanotechnology
Cambridge, United States
Caedo Oncology AS
We create improved treatment options for cancer patients through unique immunotherapy oppo...
Oslo, Norway
About EVIIVE AG
Ymmunobio is a pioneering preclinical-stage oncology biotech startup founded in 2021. Committed to revolutionizing cancer treatment, the company focuses on developing groundbreaking therapies for cancer patients. With a slogan of "Ymmunobio: Pioneering New Frontiers in Cancer Treatment," the startup is driving innovati...
Oncology Biotech, Startup, Cancer Treatment, Preclinical-stage, Antibodies Development, Immune System Modulation, Cancer Cell Proliferation, Innovative Treatments, Cancer Patient Care, Immunotherapy, Biomedical Research, Immune Response, Cancer Therapy, Drug Development, Biopharmaceutical
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around EVIIVE AG: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at EVIIVE AG on 11 Sep 2024. The 12 companies listed here were last checked between 21 Jun 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
